DLDayong Lee

Dayong Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dayong Lee has a total of 104 co-authors. Here are the top co-authors by number of shared publications:

  • Marilyn A. Huestis

    Chemistry and Drug Metabolism Section, IRP, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA

    18 shared publications
  • Garry Milman

    Chemistry and Drug Metabolism, IRP, National Institute on Drug Abuse, NIH, Biomedical Research Center, 251 Bayview Blvd. Room 05A721, Baltimore, MD 21224, USA

    11 shared publications
  • Peter Stout

    Toxicology, Houston Forensic Science Center

    8 shared publications
  • Allan J. Barnes

    Chemistry and Drug Metabolism, IRP, National Institute on Drug Abuse, NIH, Biomedical Research Center, 251 Bayview Blvd. Room 05A721, Baltimore, MD 21224, USA

    7 shared publications
  • Allan J Barnes

    Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, NIH, Baltimore, MD

    5 shared publications
  • Damodara R. Mendu

    Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, NIH, Baltimore, MD, USA

    5 shared publications

Latest Publications

  • Antemortem toxicological and behavioral findings of drivers involved in fatal traffic crashes: a comparative analysis of charged and uncharged individuals

    by Dayong Lee, Salvador R. Corral, Akilah Mance, Peter Stout

    Alcohol/drug-related impairment and unsafe driving behaviors such as speeding, running red lights, or failure to wear a seat belt have been identified as contributing factors to road traffic accidents. This study aims to examine antemortem toxicological testing results, driving behaviors and other characteristics of drivers involved in fatal traffic crashes, which may offer insights into the broader spectrum of fatal crash risk factors. Toxicological results and case data including demographic characteristics and driving behaviors were analyzed for drivers charged in fatal traffic crashes and thus potentially culpable between 2019 and 2024. These individuals were compared with drivers involved in fatal collisions who had not been charged. Whether a driver was charged with an accident depended not only on culpability but also on the availability of sufficient evidence, the presence of criminal negligence, legal/procedural considerations, contributory faults, and other contextual factors. All drivers survived the accidents and provided antemortem blood samples, which were submitted by the Houston Police Department (HPD) for alcohol and drug testing to the Houston Forensic Science Center (HFSC). Based on offense classifications in the HFSC database, HPD reports, and court records, 116 drivers were identified as suspects charged in fatal crashes in 2019-2024. Among the charged drivers, 81% were male with an average age of 32 years (range: 17-62), and 97% tested positive for alcohol and/or drugs. Ethanol was the most frequently detected substance (73%), followed by cannabinoids (47%) and cocaine/metabolites (12%). Common unsafe driving behaviors included speeding/failure to control speed (53%), lane deviation (31%), and running red lights/stop signs (20%). In comparison, of 87 uncharged drivers (82% male, average age 40 years) involved in fatal crashes, 61% tested negative for both alcohol and drugs. Among the 39% who tested positive, cannabinoids (17%) and ethanol (9%) were the most frequently detected drugs. The majority (91%) of the charged drivers committed one or more traffic infractions. Failure to control speed/speeding was the most common (53%), followed by failure to drive in a single lane (31%). In contrast, the majority (64%) of the uncharged drivers did not commit a traffic infraction. The present research revealed several risk factors of fatal traffic crashes - younger male drivers with high blood alcohol concentrations, drug-impaired drivers who failed to control speed or to drive in a single lane, pedestrians who did not yield the right of way to vehicle, and motorcyclists who sped. Targeting these risk factors could aid in addressing the increasing number of traffic fatalities.

  • Application of professional best practices in postmortem forensic toxicology

    by Michael T Truver, Chris W Chronister, Gregory G Davis, Teresa R Gray, Rebecca L Hartman, Joseph H Kahl, Erin L Karschner, Sarah Kerrigan, Robert Kronstrand, Alex J Krotulski, et al.

    Postmortem forensic toxicology plays a critical role in medicolegal death investigations through the identification and quantitation of drugs and other substances in postmortem fluids and tissues. Due to the complexity of this sub-discipline, consistent application of best practices is critical for ensuring accurate and reliable results, particularly in the context of challenges such as emerging novel psychoactive substances, complex poly-drug interactions, postmortem drug redistribution, and analytical limitations inherent with postmortem specimens. Although there has been significant progress in the development of consensus-based forensic toxicology standards, their scope is intentionally broad to accommodate human performance, postmortem, regulated and non-regulated employment drug testing, court-ordered toxicology, and other applications. Consequently, some aspects specific to postmortem toxicology and medicolegal death investigation are not addressed within the standards. This manuscript seeks to fill these gaps by demonstrating how current standards can be applied in a postmortem toxicology setting and presenting best practices in situations where no established standards exist. These best practices will aid laboratories in prioritizing changes to workflows, allocating resources more efficiently, improving analytical accuracy and reproducibility, ensuring interpretative consistency, and strengthening forensic defensibility in administrative and legal proceedings. Key topics addressed include specimen collection and case submission protocols, method validation approaches tailored for postmortem analysis, optimized analytical workflows based on testing scope and case classification, and quality assurance requirements. Considerations for data review, reporting, and result interpretation are discussed in the context of accurate determination of cause and manner of death. Emphasis is placed on integrating toxicological findings with investigative and autopsy information obtained through ongoing communication with stakeholders. By integrating the application of existing consensus standards with the best community practices for postmortem toxicology, this manuscript aims to support the generation of robust and reliable toxicological data, with the goal of improving forensic investigations, public health surveillance, and drug policy development.


  • Evaluation of sevoflurane interference with forensic blood ethanol analysis, including sevoflurane stability, and an authentic case

    by Charles Perkins, Corissa Rodgers, Peter Stout, Dayong Lee

    Sevoflurane, a volatile anesthetic routinely used in clinical settings, was investigated to determine the extent of its interference with in-house forensic blood ethanol analysis. This potential interference could have a significant impact on the analysis and subsequently the interpretation of ethanol in human performance antemortem forensic toxicology casework (e.g. Driving While Under the Influence (DWI) cases). Aqueous samples with ethanol concentrations spanning 0.02–0.40 g/100 mL were fortified with sevoflurane and analyzed using two different dual-column headspace-­gas chromatography with flame ionization detection instruments. Sevoflurane was found to elute as an interference peak near ethanol on column 1 (BAC1) and co-elute with ethanol on column 2 (BAC2); the differences were due to the column chemistries. Analyte identification and quantification acceptance criteria monitored included peak-to-valley ratio (resolution) and percent difference between individual column concentrations and the average value of both column concentrations. A 2023 DWI case exhibited potential sevoflurane interference and demonstrated the importance of ethanol reporting acceptance criteria for detecting such interference. In the majority of experiments with sevoflurane and ethanol present in the samples, sevoflurane presence caused failing acceptance criteria to report ethanol results, but if acceptance criteria were met, the ethanol concentration was slightly elevated. An additional sevoflurane stability study showed that the highly volatile sevoflurane could evaporate between analysis and re-analysis of blood samples due to additional tube openings. The decrease of sevoflurane was monitored at each opening of the tube using relative peak areas. HFSC re-analyzes suspected sevoflurane samples, as the additional tube openings could allow sevoflurane to evaporate.


  • Toxicological and demographic profiles of phencyclidine-impaired driving cases in Houston: updates from the 2019 to 2023 data

    by Dayong Lee, Salvador R Corral, Cassandra Duvall, Peter Stout

    Phencyclidine (PCP) is a dissociative anesthetic harmful to road traffic safety as the drug may impair driving performance by inducing adverse effects such as sedation, ataxia, agitation, disorientation, and confusion. Houston Forensic Science Center previously reported toxicological and demographic characteristics of PCP-impaired driving cases in Houston from 2013 to 2018 and presently reports the 2019–23 cases. The blood samples collected from suspect drivers were analyzed for alcohol and drugs and those positive for PCP at the reporting limit of 5 ng/mL were included in the study (n = 1375). The drivers had the median (mean, range) PCP concentration of 45 (49, 5–170) ng/mL and were mostly males (77%) and black (89%) with the mean age of 40 years. More than half of the drivers (59%) were polydrug users with cannabinoids being the most frequently detected (39%), followed by cocaine/metabolites (15%) and ethanol (10%). Compared to our previous findings and other studies, the PCP concentration distributions and concurrent drug profiles of the drivers were remarkably consistent despite multiple changes in the drug market over the years; their demographics also remained comparable except for the mean age, which continued to increase. Continual surveillance of PCP-impaired driving cases is important to identify risk groups and aid in reducing this hazardous driving behavior, so prevalent and persistent in the city of Houston.


  • Ethanol stability from 9 years of a blind quality control program in blood alcohol analysis

    by Erika Phung, Corissa Rodgers, Andrea Gooden, Peter Stout, Dayong Lee

    A blind quality control (BQC) program in blood alcohol analysis was implemented at the Houston Forensic Science Center (HFSC) in September 2015. By mimicking authentic toxicology blood evidence, the laboratory can perform a concurrent evaluation of their technical and administrative casework procedures and test the accuracy and reliability of their volatile analysis method in a format that is blinded to the analyst. From September 2015 to November 2023, HFSC’s Quality Division submitted 1228 antemortem whole blood samples: 292 ethanol-negative samples and 936 ethanol-positive samples at sixteen target concentrations (0.051, 0.080, 0.100, 0.110, 0.120, 0.130, 0.150, 0.160, 0.170, 0.180, 0.190, 0.200, 0.230, 0.240, 0.250, and 0.260 g/dL). A second, unopened blood tube in 168 of the 1228 BQCs was also analyzed after 721–1140 days: 24 ethanol-negative samples and 144 ethanol-positive samples at five target concentrations (0.080, 0.100, 0.130, 0.180, and 0.240 g/dL). All 316 ethanol-negative samples remained negative. After 42–758 days, the average (median, range) change in ethanol concentration of the 936 positive samples was -1.4% (-1.3%, -12.0% to +8.4%) with a statistically significant difference (P < 0.001) observed for the gradual decline in blood alcohol concentration (BAC) over time. The average BAC percentage differences per target concentration, ranged from -6.4% (-0.008 g/dL) to +5.7% (+0.011 g/dL), were within HFSC’s current measurement uncertainty (9.4% at k=3), showing no apparent correlation between the change in ethanol and the theoretical target concentration. As the analysis time between the two blood specimens from the same evidence kit extended, the loss in ethanol significantly increased (P < 0.001).


  • Interference of the novel designer benzodiazepine 4ʹ-chloro deschloroalprazolam with alprazolam analysis in toxicology and seized drug DUID casework

    by Jami D Reber, Corissa Rodgers, Jessica L Ayala, James Miller, Peter Stout, Dayong Lee

    In recent years, the emergence of the novel designer benzodiazepine 4ʹ-chloro deschloroalprazolam has presented a new challenge for forensic laboratories by interfering with the identification and quantitation of alprazolam. As an isomer of alprazolam, 4ʹ-chloro deschloroalprazolam has similar physicochemical properties and can be misidentified in casework samples as alprazolam without a specific method to differentiate the two analytes. Starting in late 2021, the Houston Forensic Science Center (HFSC) received toxicological and seized drug evidence indicating the presence of 4ʹ-chloro deschloroalprazolam. An interference study was performed to supplement the laboratory’s validated benzodiazepines method for toxicological samples to differentiate alprazolam from 4ʹ-chloro deschloroalprazolam. This study showed that while the isomers could not be chromatographically resolved using the current method, they could be differentiated based on their retention times relative to the internal standard, alprazolam-d5. Based on these findings, the HFSC toxicology laboratory reports test results as “unsuitable for analysis due to an interference” if a suspected alprazolam peak elutes before the alprazolam-d5 peak, even if all identification and quantification criteria (e.g., retention time) were acceptable. Additionally, the seized drug and toxicology laboratories re-evaluated previously analyzed alprazolam-positive casework to determine if suspected 4ʹ-chloro deschloroalprazolam had been misidentified as alprazolam. This report presents three cases: one case with toxicological evidence indicating the presence of both 4ʹ-chloro deschloroalprazolam and alprazolam, and two cases with both seized drug material and toxicology evidence indicating the presence of 4ʹchloro deschloroalprazolam with no detected alprazolam.


  • Evaluation of suspected drug‐facilitated sexual assault cases in the city of Houston from 2014 to 2020

    by Sara K. Dempsey, Corissa L. Rodgers, Peter Stout, Dayong Lee

    Drug‐facilitated sexual assault is a form of sexual violence against an individual incapacitated by alcohol and/or drugs consumed voluntarily or covertly administered. The purpose of this study was to evaluate toxicological results and the associated demographics of sexual assault‐related cases submitted to Houston Forensic Science Center from 2014 to 2020. In total, 1240 samples (1230 cases) were tested during the six‐year period that consisted of blood, urine, or both specimens. Blood was analyzed for ethanol by dual‐column headspace gas chromatography with flame ionization detection. Drug screen analysis was performed preferably on urine specimens using enzyme‐linked immunosorbent assay. Positive screening results were confirmed upon request only due to laboratory policy. A total of 22% (n = 176) of requested samples were confirmed positive. Ethanol was the most prevalent substance detected, present in 17% of the samples (n = 212), followed by 11‐nor‐9‐carboxy‐delta‐9‐tetrahydrocannabinol (THC‐COOH) (n = 118). The combination of ethanol and THC‐COOH was the most frequent one found (n = 17) in cases positive for two or more drugs (n = 101). Demographic data showed the majority of DFSA victims were white (25%) females (72%) with an average age of 27 years old (n = 348). Almost 90% of cases where the presence of drugs was confirmed resulted in no charges being made, either due to lack of suspect information or unknown reasons by the laboratory.


  • A Comparison of High Drug Concentrations in Impaired Driving and Postmortem Casework in Harris County, TX

    by Sara K Dempsey, Teresa R Gray, Anna T Kelly, Peter Stout, Dayong Lee

    Drug-impaired driving is a growing public safety issue. Addressing impairment due to drugs other than ethanol can be challenging for forensic toxicologists as many factors need to be considered including the type of drug(s), drug−drug interaction, the dose(s) and the individual’s physiological condition and drug use history. Interpretation of blood drug test results is additionally difficult as drug concentrations in impaired driving cases may overlap levels typically viewed as toxic. This study compares blood concentrations of drugs in impaired driving cases to those in postmortem cases in Houston, TX, from 2014 to 2020. Blood drug concentrations from driving while intoxicated (DWI) or driving under the influence of drugs (DUID) cases submitted to Houston Forensic Science Center (HFSC) and Harris County Institute of Forensic Sciences (HCIFS) were compared to postmortem blood test results from HCIFS. Eight DWI/DUID cases had drugs that exceeded impaired driving concentrations reported in the literature. These drugs included fentanyl (220 ng/mL), oxycodone (680 ng/mL), hydrocodone (310 and 490 ng/mL), clonazepam (330 ng/mL), methamphetamine (3,500 and 7,100 ng/mL) and tetrahydrocannabinol (THC) (160 ng/mL). For oxycodone and hydrocodone, the presented DWI/DUID cases exceeded 91% and 96% of postmortem concentrations, respectively. The 7,100 ng/mL methamphetamine DWI/DUID result was greater than 98% of postmortem cases. The presented DWI/DUID concentrations were higher than all but one postmortem case for clonazepam and higher than all postmortem cases for THC. This study demonstrates that extremely high drug concentrations in DWI/DUID casework blur the line between therapeutic/recreational and toxic concentrations.